



**University of  
Zurich**<sup>UZH</sup>

**Zurich Open Repository and  
Archive**

University of Zurich  
University Library  
Strickhofstrasse 39  
CH-8057 Zurich  
[www.zora.uzh.ch](http://www.zora.uzh.ch)

---

Year: 2012

---

## **Reply to nevin**

Schlagenhauf, Patricia ; Blumentals, William A ; Suter, Pia ; Regep, Loredana ; Vital-Durand, Gabriel ;  
Schaerer, Martin T ; Boutros, Margarita Suarez ; Rhein, Hans-Georg ; Adamcova, Miriam

DOI: <https://doi.org/10.1093/cid/cis611>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-65444>

Journal Article

Published Version

Originally published at:

Schlagenhauf, Patricia; Blumentals, William A; Suter, Pia; Regep, Loredana; Vital-Durand, Gabriel;  
Schaerer, Martin T; Boutros, Margarita Suarez; Rhein, Hans-Georg; Adamcova, Miriam (2012). Reply  
to nevin. *Clinical Infectious Diseases*, 55(8):1168-1169.

DOI: <https://doi.org/10.1093/cid/cis611>

We disagree that the use of this methodology should limit the usefulness of our data. Pregnant women are routinely excluded from clinical trials. For many medications that are initially contraindicated in pregnancy, the use of drug safety databases constitutes an important tool for assessing safety during pregnancy. Our analysis provides physicians and patients with information for the evaluation of benefit and risk in women of child-bearing potential exposed to mefloquine.

Our main outcome measures were descriptive birth defect reporting prevalence and types of malformations. We also provided limited data on fetal loss and reviewed all literature on this subject including the references that Nevin cites in his letter and other references that he omitted to mention. Fetal loss or miscarriage is difficult to quantify in any population due to ascertainment bias [4], and epidemiological data from previous studies show varying results: a Thai study reported an increased risk of miscarriage in 159 mefloquine prophylaxis users [5], whereas a second larger study in Malawi showed no increase in stillbirths in women receiving mefloquine prophylaxis ( $n = 1032$ ) [6].

Nevin refers to the use of sulfadoxine-pyrimethamine as intermittent treatment in the developing world for pregnant women. This is a separate topic that we did not address. Our paper is concerned with malaria prophylaxis in pregnant women from industrialized countries who cannot defer travel to malaria-endemic areas.

Dr Nevin's other letter [7] suggests a biological mechanism linking mefloquine to pregnancy loss. This proposed mechanism warrants further inquiry but because it is a hypothesis, based on non-clinical data, it should be interpreted with caution in the human context.

Various factors, such as age and exposure to malaria, could contribute to the loss of pregnancy in women traveling to endemic areas. A large study from Denmark showed that the risk of spontaneous abortion in women aged 20–24

### Reply to Nevin

We agree with Nevin [1] that the post-marketing surveillance methodology of our article [2] has similarities with the analysis published in 1998 by Vanhauwere and colleagues [3]. We appropriately referenced the aforementioned paper in our publication. Our methodology however, differs in that we separately analyzed maternal, paternal, and both-parent exposure to mefloquine, and the time period for our study was significantly longer (1986–2010) [2]. Furthermore, for comparison, we provided background rates for pregnancy outcomes in the general population.

is 8%–9%, rising with age to 74.7% in women aged >45 years [8]. Exposure to malaria further increases the risk of fetal loss. A recent analysis found that a single episode of *Plasmodium falciparum* or *Plasmodium vivax* malaria could cause miscarriage [9].

Malaria in women of childbearing potential needs to be prevented. The recent data on imported malaria in the US report 41 cases in pregnant women in 2010, the majority traveling to Africa and not using a chemoprophylaxis [10]. In 2011, the Food and Drug Administration reclassified mefloquine from pregnancy category C to category B. The Centers for Disease Control and Prevention recommends mefloquine prophylaxis in all trimesters of pregnancy for women who cannot defer travel to high-risk, malaria-endemic areas [11].

## Note

**Potential conflicts of interest.** P. S. has received research funding, honoraria for speaking at conferences, and consultancy fees from F. Hoffmann-La Roche and honoraria from Glaxo-SmithKline and Sigma-Tau Pharmaceuticals. W. A. B., P. S., L. R., G. V.-D., M. T. S., M. S. B., H.-G. R., and M. A. are employees of F. Hoffmann-La Roche.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Patricia Schlagenhauf,<sup>1</sup> William A. Blumentals,<sup>2</sup> Pia Suter,<sup>2</sup> Loredana Regep,<sup>2</sup> Gabriel Vital-Durand,<sup>2</sup> Martin T. Schaerer,<sup>2</sup> Margarita Suarez Boutros,<sup>2</sup> Hans-Georg Rhein,<sup>2</sup> and Miriam Adamcova<sup>2</sup>

<sup>1</sup>University of Zurich Centre for Travel Medicine, World Health Organization Collaborating Centre on Travel and Health, Institute for Social and Preventive Medicine, Zurich, and <sup>2</sup>F. Hoffmann-La Roche, Basel, Switzerland

## References

1. Nevin RL. Limitations of post-marketing surveillance in the analysis of risk of pregnancy loss associated with maternal mefloquine exposure. *Clin Infect Dis* 2012; 55:1167–8.
2. Schlagenhauf P, Blumentals WA, Suter P, et al. Pregnancy and fetal outcomes after exposure to mefloquine in the pre- and periconception period and during pregnancy. *Clin Infect Dis* 2012; 54:e124–31.
3. Vanhauwere B, Maradit H, Kerr L. Postmarketing surveillance of prophylactic mefloquine (Lariam®) use in pregnancy. *Am J Trop Med Hyg* 1998; 58:17–21.
4. Committee for Medicinal Products for Human Use (CHMP). Guideline on the exposure to medical products during pregnancy: need for post-authorisation data, London: European Medicines Agency, May 2006. [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/Regulatory\\_and\\_procedural\\_guideline/2009/11/WC500011303.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/11/WC500011303.pdf). Accessed 7 June 2012.

5. Nosten F, ter-Kuile K, Maelankiri L, et al. Mefloquine prophylaxis prevents malaria during pregnancy: a double-blind, placebo-controlled study. *J Infect Dis* 1994; 169:595–603.
6. Steketee RW, Wirima JJ, Slutsker L, Khoroana CO, Heymann DL, Breman JG. Malaria treatment and prevention in pregnancy: indications for use and adverse events associated with use of chloroquine or mefloquine. *Am J Trop Med Hyg* 1996; 55:50–6.
7. Nevin RL. Mefloquine blockade of connexin 43 (Cx43) and risk of pregnancy loss. *Placenta* 2011; 32:712.
8. Nybo Anderson AM, Wohlfart J, Christens P, Olsen J, Melbye M. Maternal age and fetal loss: population based register study. *BMJ* 2000; 320:1708–12.
9. McGready R, Lee SJ, Wiladphaingern J, et al. Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population based study. *Lancet Infect Dis* 2012; 12:388–96.
10. Mali S, Kachur SP, Arguin PM. Malaria surveillance—United States 2010. *MMWR Morbid Mortal Wkly Rep* 2012; 61:1–17.
11. Centers for Disease Control and Prevention (CDC). Available at: [http://www.cdc.gov/malaria/new\\_info/2011/mefloquine\\_pregnancy.html](http://www.cdc.gov/malaria/new_info/2011/mefloquine_pregnancy.html). Accessed 7 June 2012.

Correspondence. Professor Patricia Schlagenhauf, PhD, University of Zurich Centre for Travel Medicine, WHO Collaborating Centre for Travellers' Health, Institute for Social and Preventive Medicine, Hirschengraben 84, 8001 Zurich, Switzerland (pat@ifspm.uzh.ch).

**Clinical Infectious Diseases** 2012;55(8):1168–9

© The Author 2012. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.  
DOI: 10.1093/cid/cis611